fda warning compounded semaglutide october 2025 📢 has determined the shortage of injection products, a glucagon-like peptide 1 (GLP-1) medication, is resolved. Patients and prescribers may still see intermittent and limited localized supply disruptions as the Drugmakers battle pharmacies over compounded

The majority of participants in the treatment group (86.4%) lost 5% of their body weight or more compared to 31.5% on placebo

After adjustment of the model for weight loss, associations between the groups and headache outcomes did not remain statistically significant although a trend towards better headache outcomes in the GLP-1-RA group was noted

In summary, GLP-1 RAs, through weight loss and the reduction of pro-inflammatory cytokines [31, 33], could provide a complementary approach to standard therapies for HS, especially in patients with obesity [36]

You also get far lower carb, fat, sugar and calories than in the heavily advertised flagship nutrition drinks you see on TV